Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Primary Care

Journal Scan / Research · June 25, 2023

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children Aged 12 to 23 Months

The Journal of Infectious Diseases

 

Additional Info

The Journal of Infectious Diseases
Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12-23 Months of Age
J. Infect. Dis 2023 May 29;227(11)1293-1302, J Díez-Domingo, X Sáez-Llorens, MA Rodriguez-Weber, C Epalza, A Chatterjee, CH Chiu, CY Lin, AA Berry, F Martinón-Torres, F Baquero-Artigao, JM Langley, JT Ramos Amador, JB Domachowske, LM Huang, NC Chiu, S Esposito, P Moris, T Lien-Anh Nguyen, V Nikic, W Woo, Y Zhou, I Dieussaert, A Leach, A Gonzalez Lopez, N Vanhoutte

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading